Key Takeaways Tempus AI is expanding its algorithms beyond oncology into pathology, radiology, cardiology and neuropsych.TEM secured two FDA 510(k) clearances for its cardiac imaging update and ECG-Low EF software. Tempus AI strengthened its platform by acquiring Arterys in 2022 and Paige's digital pathology dataset. Tempus AI (TEM) is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital path ...